Browse studies

Find your next paid study

1 recruiting study matching your filters

Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma

To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR…

Relapsed/Refractory Myeloma

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06066359